Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ruthenium anticancer drugs

CONTROLLING PLATINUM, RUTHENIUM, AND OSMIUM REACTIVITY FOR ANTICANCER DRUG DESIGN... [Pg.1]

A. General Features of Ruthenium-Arene Anticancer Drugs 24... [Pg.1]

In our group, a major part of our research is devoted to the design of new anticancer drugs. Our recent efforts towards the discovery of new platinum-, ruthenium- and osmium-based anticancer agents provide the topic for this account and a section is devoted to each metal. We focus on recent results from our lab in the context of other developments and related research in this field (hence our coverage of the field is focused on these areas and is not comprehensive). [Pg.2]

Fig. 2. Ligand substitution as a prodrug strategy for metallochem-otherapeutics (a) general scheme of prodrug activation by ligand substitution hydrolysis of a metal—halide bond is a typical activation pathway of metal-based anticancer drugs, as exemplified by the activation of cisplatin (b) and a ruthenium—arene complex (c). Fig. 2. Ligand substitution as a prodrug strategy for metallochem-otherapeutics (a) general scheme of prodrug activation by ligand substitution hydrolysis of a metal—halide bond is a typical activation pathway of metal-based anticancer drugs, as exemplified by the activation of cisplatin (b) and a ruthenium—arene complex (c).
This work provides important evidence for elucidating the cytotoxic effect of the ruthenium-arene complexes and the influence of the arene thereon, for instance with respect to excision repair of DNA lesions and DNA destabilization. It also established two different classes of Ru(II) arene anticancer drugs, i.e. those bearing an arene that has the possibility to intercalate and those that do not. This distinction is important as we will see further differences in DNA binding interactions for these two classes (vide infra). [Pg.42]

We started this section by stating that the advent of bioorganometallics provides the medicinal chemist with access to new types of reactivity and therefore with new opportunities for anticancer drug design. Our studies on the ruthenium-arene... [Pg.49]

Controlling Platinum, Ruthenium,and Osmium Reactivity for Anticancer Drug Design... [Pg.521]

Alessio E, Mestroni G, Bergamo A, Sava G (2004) Ruthenium anticancer drugs. In Sigel H (ed) Metal Complexes in Tumor Diagnosis and as Anticancer Agents. CRC Press, USA, pp 323-351... [Pg.49]

Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ (2006) Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg Chem 45 9006-9013... [Pg.51]

Ang WH, De Luca A, Chapuis-Bemasconi C, Juillerat-Jeanneret L, Lo Bello M, Dyson PJ (2007) Organometallic ruthenium inhibitors of glutathione-S-transferase Pl-1 as anticancer drugs. ChemMedChem 2 1799-1806... [Pg.55]

Dale LD, Tocher JH, Dyson TM, Edwards DI, Tocher DA (1992) Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound. AntiCancer Drug Des 7 3-14... [Pg.75]

See other pages where Ruthenium anticancer drugs is mentioned: [Pg.384]    [Pg.384]    [Pg.1]    [Pg.1]    [Pg.2]    [Pg.16]    [Pg.21]    [Pg.21]    [Pg.21]    [Pg.22]    [Pg.23]    [Pg.28]    [Pg.29]    [Pg.32]    [Pg.32]    [Pg.32]    [Pg.37]    [Pg.38]    [Pg.44]    [Pg.50]    [Pg.55]    [Pg.57]    [Pg.667]    [Pg.87]    [Pg.25]    [Pg.49]    [Pg.57]    [Pg.380]    [Pg.759]   
See also in sourсe #XX -- [ Pg.2 ]



SEARCH



Anticancer drugs

Organometallic ruthenium -arene anticancer drugs

Ruthenium anticancer agents/drugs

Ruthenium anticancer drug complexes

Ruthenium anticancer drug reactivities

Ruthenium-Arene Anticancer Drugs

© 2024 chempedia.info